HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Rule For Mandatory Supplement Registration Would Likely Give FDA Authority For Fines

ODSP Head Advises Stakeholders To Expect Congress To Open DSHEA

Executive Summary

“We would certainly want to have some enforcement and be able to utilize that enforcement,” says ODSP acting director Cara Welch. Stakeholders opposed to the change should “get comfortable with the idea of opening up DSHEA and should most certainly be part of the discussion.”

You may also be interested in...



Congressional Report Highlights Lack of Mandatory Supplement Listing As DSHEA 2.0 Talks Continue

The Congressional Research Service published a dietary supplements report on 20 September that provides an overview of the industry and current regulatory issues, including ‘limitations’ in the US FDA’s authority over supplements and, in particular, the absence of mandatory product listing.

Dietary Ingredient Advisory List Yet To Fulfill Potential For US FDA

"We haven't utilized the ingredient advisory list quite as much as I'd like to see. But it's something we'll be working on this year,” says Cara Welch, acting director of FDA’s Office of Dietary Supplement Programs.

In US, Does NDI Indicate ‘Not Delivering Innovation’ Rather Than ‘New Dietary Ingredient’?

Why stakeholders have many questions and why so many ingredients that weren’t cleared by FDA are rampant in the US are questions at the heart of resolving disagreement between the industry and the agency over regulation both sides acknowledge is biggest impediment to market growth.

Related Content

Topics

UsernamePublicRestriction

Register

RS151547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel